Algeta ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Algeta ASA's Radium-223 Dichloride in Cooperation with Bayer Receives Priority Review to the New Drug Application from FDA
Algeta ASA announced that Bayer has received notification from the US Food and Drug Administration (FDA) granting priority review of the New Drug Application (NDA) filed in December 2012 for the investigational oncology compound radium-223 dichloride (radium- 223). The application is under review for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.
Latest Developments for Algeta ASA
- Algeta ASA confirms that it is in receipt of preliminary acquisition proposal from Bayer AG
- Algeta ASA's Partner Bayer Receives Marketing Authorisation from European Commission for Xofigo
- EMA Recommends Algeta ASA's Radium Ra 223 Dichloride Developed in Cooperation with Bayer for Approval
- United States FDA Approves Algeta ASA's Xofigo
- Share this
- Digg this